On April 2, 2026, Context Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug CTIM-76, a Claudin 6 x CD3 T cell engaging bispecific antibody. This designation is specifically for the treatment of platinum-resistant ovarian cancer (PROC) in patients who have already undergone all standard care therapies. The Fast Track designation is a significant milestone for Context Therapeutics, as it highlights the potential of CTIM-76 to address a critical unmet medical need in the oncology space. The company is currently conducting a Phase 1 clinical trial to evaluate the safety and efficacy of CTIM-76 in patients with CLDN6-positive advanced or metastatic cancers, including ovarian, endometrial, and testicular cancers. Interim data from this trial is expected to be released in June 2026. The Fast Track program is designed to expedite the development and review of drugs that demonstrate the potential to treat serious conditions, aiming to bring important therapies to patients more quickly. Context Therapeutics is committed to advancing its clinical programs and is optimistic about the prospects of CTIM-76 in improving outcomes for patients with PROC. The company plans to share further updates as the clinical trial progresses and interim data becomes available.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.